Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?
Executive Summary
While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.
You may also be interested in...
Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris
Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.
Teva, Sandoz, Mylan, Pfizer…Who Sees Value In The US Biosimilars Market?
While 2018 was a record year for US biosimilar approvals and launches, companies are still struggling for market share in certain therapies and facing obstacles in getting their products over the line. Generics Bulletin rounds up where the leading players stand, ahead of financial results being published in the coming days and weeks.
Samsung Bioepis’ Trastuzumab Biosimilar Is Third Cleared By FDA – But The Market Hasn’t Formed Yet
Sued by Herceptin sponsor Genentech for patent infringement, Samsung Bioepis has legal hurdles to navigate before it can roll out its trastuzumab biosimilar in the US, which has just become the third biosimilar of the cancer treatment greenlit by the FDA.